Patent US10709671

Use of cannabinoids in the treatment of epilepsy
[+] Show Details

US10709671

1. A method of treating focal seizures in Dravet Syndrome, comprising administering to a subject in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) and comprises no more than 0.15% (w/w) Δ9-tetrahydrocannabidiol, wherein the CBD is administered at a dose of from 15 mg/kg/day to 20 mg/kg/day. (6) (0)

2. The method of claim 1, wherein the focal seizures are focal seizures with impairment. (0)

3. The method of claim 1, wherein the Dravet Syndrome is treatment-resistant. (0)

4. The method of claim 1, wherein the CBD is administered in combination with one or more concomitant anti-epileptic drugs (AED). (1) (0)

5. The method of claim 1, wherein the CBD is a highly purified extract of cannabis. (1) (0)

7. The method of claim 1, wherein the CBD is present as a synthetic compound. (0)

9. The method of claim 1, wherein the CBD is administered as an oral composition comprising cannabidiol (CBD), a solvent, a co-solvent, a sweetener, and a flavouring. (6) (0)

10. The method of claim 9, wherein the solvent is sesame oil. (0)

11. The method of claim 9, wherein the co-solvent is ethanol. (0)

12. The method of claim 9, wherein the sweetener is sucralose. (0)

13. The method of claim 9, wherein the flavouring is strawberry flavour. (0)

14. The method of claim 9, wherein the CBD is present at a concentration of between 25 mg/ml and 100 mg/ml. (0)

15. The method of claim 9, wherein the composition comprises cannabidiol (CBD) at a concentration of between 25 to 100 mg/ml, ethanol as co-solvent at a concentration of 79 mg/ml, sucralose as sweetener at a concentration of 0.5 mg/ml, strawberry flavouring as flavouring at a concentration of 0.2 mg/ml, and sesame oil as solvent q.s. to 1.0 ml. (0)

16. A method of treating focal seizures in Dravet Syndrome, comprising administering to a subject in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) and comprises no more than 0.15% (w/w) Δ9-tetrahydrocannabidiol, wherein the CBD is administered at a dose of 20 mg/kg/day. (6) (0)

17. The method of claim 16, wherein the focal seizures are focal seizures with impairment. (0)

18. The method of claim 16, wherein the Dravet Syndrome is treatment-resistant. (0)

19. The method of claim 16, wherein the CBD is administered in combination with one or more concomitant anti-epileptic drugs (AED). (1) (0)

20. The method of claim 16, wherein the CBD is a highly purified extract of cannabis. (1) (0)

22. The method of claim 16, wherein the CBD is present as a synthetic compound. (0)

24. The method of claim 16, wherein the CBD is administered as an oral composition comprising cannabidiol (CBD), a solvent, a co-solvent, a sweetener, and a flavouring. (0)

View Abstract and Specification Size

PDF with Images and Document Face >

Full Text Publication >

Patent US10709671

Use of cannabinoids in the treatment of epilepsy

Patent Matrix® Search